论文部分内容阅读
药品专利与公共健康之争是当前国际上的一个热点问题。TRIPS协议将专利保护扩大到所有技术领域,其中包括药品领域。近年来药品专利与公共健康之间的国际争端不断。世界贸易组织(WTO)于2001年通过的多哈宣言以及2003年的多哈宣言第六段执行决议,反映了国际社会对此问题的关注和重视。本文着眼于WTO背景下药品专利与公共健康之间的冲突问题,对冲突的形成原因和协调途径进行了分析和论证,并提出在当前的形势下对如何平衡两者利益的一些建议和看法。
Drug patent and public health controversy is currently a hot issue in the international community. The TRIPS agreement extends patent protection to all technical areas, including the pharmaceuticals area. In recent years, international disputes between pharmaceutical patents and public health have continued. The implementation of the resolution by the WTO in the Doha Declaration adopted in 2001 and paragraph 6 of the 2003 Doha Declaration reflects the international community’s concern and attention to this issue. This article focuses on the conflict between drug patents and public health in the context of WTO, analyzes and argues for the causes of formation and coordination of conflicts, and puts forward some suggestions and opinions on how to balance the interests of both under the current situation.